Press Releases for RIGL

Press Releases
Rigel Announces Second Quarter 2009 Financial Results
The Rosen Law Firm, P.A. Encourages Rigel Pharmaceuticals, Inc. Shareholders to Evaluate Their Legal Rights
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Rigel to Present at Jefferies Healthcare Conference
Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
Rigel to Present at JMP Securities Research Conference
Rigel Announces First Quarter 2009 Financial Results
Rigel to Present at Citi's Biotech Day
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Rigel to Present at Keystone Symposia Conference - Mar 12 2009 8:15AM
Rigel to Present at Barclays Capital Healthcare Conference
Rigel Announces Fourth Quarter and Year End 2008 Financial Results
Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Bronstein, Gewirtz & Grossman, LLC Announces That a Class Action Has Been Filed Against Rigel Pharmaceuticals, Inc.
Brower Piven Encourages Investors Who Have Losses in Excess of $200,000 From Investment in Rigel Pharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the April 7, 2009 Lead Plaintiff Deadline
The Shuman Law Firm Announces a Securities Class Action Lawsuit Has Been Filed On Behalf of Investors of Rigel Pharmaceuticals, Inc.
Izard Nobel LLP Announces Class Action Lawsuit Against Rigel Pharmaceuticals, Inc.
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Rigel Pharmaceuticals, Inc.
The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Rigel Pharmaceuticals, Inc.
Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Rigel Pharmaceuticals, Inc.
Rigel to Present at BIO CEO & Investor Conference
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Rigel to Host Conference Call on February 3, 2009
Rigel to Present at Keystone Symposia Conference - Jan 23 2009 7:46AM
Rigel to Participate at the RBC Capital Markets Healthcare Conference
Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
Rigel to Present at the Piper Jaffray Annual Health Care Conference
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
Rigel to Present at the 2008 Credit Suisse Healthcare Conference
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
Rigel to Host Update Conference Call
Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
Rigel to Webcast Investor Update on October 27, 2008
Rigel to Present at JMP Securities Healthcare Focused Conference
Rigel to Present at Thomas Weisel Partners Healthcare Conference
Rigel Announces Second Quarter 2008 Financial Results
Rigel to Present at Collins Stewart Growth Conference
Rigel to Present at Jefferies Healthcare Conference
Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis
Rigel to Present at the Needham Biotechnology and Medical Technology Conference
New Analyst Reports for PACCAR INC, LKQ CORP, MICROCHIP TECHNOLOGY INC, and RIGEL PHARMACEUTICALS INC
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL
Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors - May 27 2008 1:01AM
Rigel Announces First Quarter 2008 Financial Results - Jun 2 2008 2:47AM
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model